BioTech IP Review

• Patent Number: US 11,951,212 B2
• Issue Date: April 9, 2024
• Assignee: Vertex Pharmaceuticals Incorporated
• Subject: Combination compositions and methods for treating cystic fibrosis using CFTR modulator drugs.

---

What This Patent Covers

This patent claims combination pharmaceutical compositions that treat Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)‑mediated diseases — most importantly, cystic fibrosis (CF) — by administering an effective amount of a combination of modulators that improve the function of defective CFTR proteins. The formulations are designed to be used in patients possessing specific CFTR gene mutations associated with CF.

• Combination compositions: The invention includes mixtures of CFTR modulators (e.g., correctors, potentiators) that synergistically improve mutant CFTR function.
• Methods of treatment: It covers methods of administering these compositions to treat or lessen the severity of CF in patients who carry a variety of CFTR mutations, including both common and rare variants.
• Spray dried dispersions/pharmaceutical formulations: The patent includes specific spray dried dispersion formulations or solid oral dosage forms that enhance delivery and stability of the active compounds.

---

Why This Patent Is Important

• Supports next‑generation CF therapies: Vertex’s Alyftrek (a once‑daily CFTR modulator combination) was approved by the U.S. FDA and represents a strategic evolution of its cystic fibrosis portfolio to maintain commercial strength as older patents expire.
• Covers blockbuster disease area: Cystic fibrosis is a life‑long, life‑shortening genetic disease with limited treatment options; Vertex’s CFTR modulators (including Trikafta and Alyftrek) have been major revenue drivers — Trikafta alone generated multibillion‑dollar sales and continues to shape the company’s market position.
• Extends exclusivity: By securing patents on specific compositions and treatment methods, Vertex can defend its proprietary formulations against generics and biosimilars, protecting revenue through at least the 2030s.

---

Summary

U.S. Patent No. 11,951,212 B2 protects combination compositions and administration methods for treating cystic fibrosis via CFTR modulation. These compositions underpin Vertex’s high‑value cystic fibrosis medicines (notably next‑generation triple combinations like Alyftrek), making this patent one of the company’s most commercially significant IP assets — crucial for maintaining market exclusivity and revenue in its flagship therapeutic area.